Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Atrial Fibrillation Drugs Market

Atrial Fibrillation Drugs Market Share

Report ID: GMI3253
Published Date: Apr 2019
Report Format: PDF

Download Free Sample

Atrial Fibrillation Drugs Market Share

Johnson & Johnson
Pfizer
Sanofi
Bayer AG
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
AstraZeneca

are some of the major industry players operating effectively in the global market. These key market participants will hold majority market share owing to strong financial position and better brand recognition. Major strategies implemented by these companies in the market include new product launches, expansion strategy, acquisition strategy etc. with the aim to gain competitive advantage over its peers.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of atrial fibrillation drugs exceeded USD 13 billion in 2018.

The industry share of atrial fibrillation drugs is expected to witness 3% CAGR from 2019 to 2025.

Occurrence of cardiovascular diseases in North America and Europe and rising demand for unmet atrial fibrillation drug therapy are slated to fuel the demand for atrial fibrillation drugs.

Increase in the number of patients suffering from atrial fibrillation needing restoration of sinus rhythm and upsurge in geriatric population are triggering the use of atrial fibrillation drugs in heart rhythm control.

Rampant valvular diseases in the U.S. and the palpable presence of leading drug manufacturing companies including Bristol-Myers Squibb and Johnson & Johnson are encouraging stakeholders to invest in North America.

Occurrence of significant number of atrial fibrillation drug therapies in hospitals and increase in supply agreements between hospitals and manufacturing firms have led to the use of atrial fibrillation drugs in hospitals.